Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neotherapuetics possibly has a breakthrough drug - NEOT -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (63)	12/2/1999 11:07:00 AM
From: Marty	Read Replies (2) \| Respond to of 204

Tuck, You can't imply one thing or another or feel slighted that NeuroInvest didn't answer your question. He analyzes and discusses things like the GLFD program for a living and he only posts a viewpoint on message boards when he feels like it. He also publishes an opinion on the market direction of a list of biotech stocks he follows. You can accept or reject his opinions on both or either one or none. It's strange but some biotech stocks seem to get more interest in what they are doing and move very well on news, like Titan Pharmaceuticals and Hemispherix. I guess it is that there is a long list of bio tech wannabes with something exciting in the cooker and there isn't enough interest in biotech at the moment to spread around to all of them. I think that will change and biotech will be the next big industry after technology runs its course. It just that I bought into NEOT early on and sweated through all the early tests. I view each one as passing another base on the way to home plate. It is taking a lot longer than I expected but it seems like the big risks are behind them and the drug is performing even better than expected. The potential rewards are a lot bigger than I originally thought as well. I thought it could be a 2 or even 4 bagger and now I think 10 or more is more likely. So, its a tradeoff.